GGO Vergunningendatabase

Zoekcriteria

1. Rechtspersoon:
2. Uitgangs-organisme:
3. Procedure: Alle MA IG IM-MV IM-L
4. Dossiernummer:

1. Status: Alle Ter inzage Teruggetrokken Vergunning onherroepelijk In behandeling Besluit genomen Werkzaamheden gestart Kennisgeving niet ingestemd Besluit geweigerd Procedure afgerond Vergunning vernietigd Intrekkingsbesluit onherroepelijk Ontwerpbesluit genomen Vergunning verleend
2. Datum vergunning vanaf:
3. Datum vergunning t/m:

1. Trefwoorden:

Zoekresultaat

IM-L 20-001_000	Photanol	Productie van organisch zuur met cyanobacteriën		Ontwerpbesluit genomen
IM-MV 19-008_003	Het Nederlands Kanker Instituut	Clinical Trials to Assess the Safety and/or Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells (GSK3377794), alone or in combination with other agents, in HLA-A*02:01, HLA-A*02:05 and/or HLA-A*02:06 Participants with NY-ESO-1 and/or LAGE-1a Positive Cancers	28-01-2021	Vergunning verleend
IM-MV 19-017_003	Universitair Medisch Centrum Utrecht	Clinical Trials to Assess the Safety and/or Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells (GSK3377794), alone or in combination with other agents, in HLA-A*02:01, HLA-A*02:05 and/or HLA-A*02:06 Participants with NY-ESO-1 and/or LAGE-1a Positive Cancers	28-01-2021	Vergunning verleend
IM-MV 19-021_003	Erasmus MC	Clinical Trials to Assess the Safety and/or Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells (GSK3377794), alone or in combination with other agents, in HLA-A*02:01, HLA-A*02:05 and/or HLA-A*02:06 Participants with NY-ESO-1 and/or LAGE-1a Positive Cancers	28-01-2021	Vergunning verleend
IM-MV 19-023_002	UMCG	Clinical Trials to Assess the Safety and/or Antitumor Activity of Genetically Engineered NY-ESO-1-specific (c259) T cells (GSK3377794), alone or in combination with other agents, in HLA-A*02:01, HLA-A*02:05 and/or HLA-A*02:06 Participants with NY-ESO and/or LAGE-1a Positive Cancers	28-01-2021	Vergunning verleend
IM-MV 20-001_001	UMCG	Clinical testing of TX200-TR101, an autologous antigen-specific chimeric antigen receptor (CAR) T regulatory cell therapy.	05-01-2021	Vergunning verleend
IM-MV 20-014_001	LUMC	A Phase 3 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with the LentiGlobin BB305 Lentiviral Vector in Subjects with Sickle Cell Disease	05-01-2021	Vergunning verleend
IM-MV 20-015_000	AMC	A Clinical Study to Evaluate the Safety, Reactogenicity, Immunogenicity and Efficacy of an Ad26 and/or MVA-BN clinical vector for the prevention or treatment of infectious diseases		Ontwerpbesluit genomen
IM-MV 20-017_000	LUMC	Phase I/II study of lentiviral gene transfer for SCID-X1	05-01-2021	Vergunning verleend
IM-MV 20-018_000	LUMC	Exposure of human test subjects to live genetically attenuated PfDmei2 (LA-GAP) malaria parasites	04-02-2021	Vergunning verleend
IM-MV 20-019_000	Stichting Katholieke Universiteit	Exposure of human test subjects to live genetically attenuated PfDmei2 (LA-GAP) malaria parasites	08-02-2021	Vergunning verleend
IM-MV 20-020_000	Intervet International	Ontwikkeling van een levend vaccin tegen Histophilus luchtweginfecties in kalveren		Ontwerpbesluit genomen